Search | Médecins Sans Frontières Access Campaign

386 results found
There are 5 active filters
Clear all filters
Fact sheet
Issue brief
Report
Report series
Technical brief

386 results found

Report |

11 Novembro 2024

The Broken Lens: Antimicrobial Resistance in Humanitarian Settings

MSF report on treating AMR in people caught in challenging humanitarian settings

Tags Antimicrobial resistance antimicrobial resistance

Technical brief |

06 Novembro 2024

Pandemic Agreement: MSF’s Comments on Selected Provisions of November 2024 Draft

Analysis of latest draft of Pandemic Agreement

Tags Pandemic preparedness

Report |

15 Outubro 2024

TACTIC: Test, Avoid, Cure TB in Children

Survey of adoption of WHO paediatric TB guidelines into national policy frameworks in 14 countries

Tags Tuberculosis tuberculosis

Technical brief |

09 Setembro 2024

Pandemic Agreement: MSF’s Comments on Selected Provisions of the Draft Proposal Text

MSF urges governments to build on the progress made and commit to stronger obligations

Tags Pandemic preparedness

Technical brief |

04 Setembro 2024

Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit

Recommendations for a timely, rigorous and transparent audit of the cost of producing lifesaving tests

Tags HIV/AIDS HIV/AIDS GeneXpert Treatment Action GroupCepheid Time for $5

Report |

26 Junho 2024

Secrets Cost Lives: Transparency and Access to Medical Products

Progress towards equity in access to medical products can only be built on the open sharing of information and knowledge, not on secrets

Tags Transparency

Technical brief |

05 Junho 2024

Antiretroviral Prices in 2023

Sources and prices of HIV antiretroviral (ARV) medicines in 2023

Tags HIV/AIDS HIV/AIDS Global Fund

Issue brief |

08 Maio 2024

Defeating the Double Standard in Diabetes Care

Exposing the exorbitant prices of diabetes medicines and injection devices

Tags Diabetes Diabetes Insulin

Technical brief |

29 Abril 2024

MSF’s Comments on Selected Provisions of the Proposal for the WHO Pandemic Agreement

As the negotiations for the WHO Pandemic Agreement enter the last stage, a number of critical issues need urgent attention

Tags Pandemic preparedness TRIPS

Technical brief |

25 Abril 2024

Transparency CORE: Clinical Trial Cost Reporting Toolkit

A toolkit to facilitate the analysis and publication of clinical trial costs

Tags TransparencyResearch and development

Technical brief |

18 Março 2024

Pandemic Agreement: MSF’s Comments on Selected Provisions of Revised Draft of Negotiating Text

While the new draft contains several improvements, governments must address outstanding issues to safeguard equitable access to medical products

Tags Pandemic preparedness

Thousands of demonstrators took to the streets in Delhi once again on 2 March 2011, in protest over the planned Free Trade Agreement between India and the European Union (EU) which will restrict access to life-saving medicines.Thousands of demonstrators took to the streets in Delhi once again on 2 March in protest over the planned Free Trade Agreement between India and the European Union (EU) which will restrict access to life-saving medicines.

Technical brief |

12 Março 2024

MSF Comments on intellectual property provisions in the final agreement of India-EFTA Agreement

MSF technical analysis shares problematic clauses in EFTA India FTA trade agreement

Tags Intellectual property and trade free trade agreement SwitzerlandIndia

Technical brief |

22 Fevereiro 2024

The PASTEUR Act is not the way for the US government to address antimicrobial resistance

The US PASTEUR Act falls short in addressing antimicrobial resistance

Tags Antimicrobial resistance

Children living with TB are a vulnerable and neglected group. In 2022, an estimated 1.25 million children and young adolescents fell ill with tuberculosis (TB), and more than 200,000 children died – that’s 1 death every 3 minutes.

Fact sheet |

24 Janeiro 2024

Diagnosing Paediatric TB: Challenges and Needs

We desperately need more research and development for TB diagnostics that are specifically designed for children

Tags Tuberculosis tuberculosis

Technical brief |

24 Novembro 2023

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Q&A on access to HIV prevention drug CAB-LA

Tags HIV/AIDS HIV/AIDS cabotegravir ViiV

Technical brief |

15 Novembro 2023

Access to TB Testing and Treatments: GeneXpert and Delamanid

The access barriers on lifesaving TB tools

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert CepheidOtsuka

Issue brief |

15 Novembro 2023

Addressing Antimicrobial Resistance Within Global Processes to Improve Pandemic Preparedness and Response

Ongoing PPR processes offer a promising pathway to complement and help implement pre-existing commitments on AMR

Tags Pandemic preparednessAntimicrobial resistance

Technical brief |

03 Novembro 2023

Pandemic Accord: MSF’s Comments on Equity Provisions in INB Proposal for Negotiating Text

MSF’s analysis of the proposed negotiating text of the WHO pandemic accord

Tags Pandemic preparedness World Health Organization

Fact sheet |

22 Setembro 2023

Tuberculosis: Challenges and Breakthroughs

Despite being curable, why is TB the world’s deadliest infectious disease? What tools do we have to beat the disease?

Tags Tuberculosis drug-resistant TBtuberculosis

Technical brief |

15 Setembro 2023

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Tags Pandemic preparednessIntellectual property and trade coronavirus TRIPS WTO

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

The Broken Lens: Antimicrobial Resistance in Humanitarian Settings

Pandemic Agreement: MSF’s Comments on Selected Provisions of November 2024 Draft

TACTIC: Test, Avoid, Cure TB in Children

Pandemic Agreement: MSF’s Comments on Selected Provisions of the Draft Proposal Text

Hidden Costs: GeneXpert Tests and Danaher’s Delayed Audit

Secrets Cost Lives: Transparency and Access to Medical Products

Antiretroviral Prices in 2023

Defeating the Double Standard in Diabetes Care

MSF’s Comments on Selected Provisions of the Proposal for the WHO Pandemic Agreement

Transparency CORE: Clinical Trial Cost Reporting Toolkit

Pandemic Agreement: MSF’s Comments on Selected Provisions of Revised Draft of Negotiating Text

MSF Comments on intellectual property provisions in the final agreement of India-EFTA Agreement

The PASTEUR Act is not the way for the US government to address antimicrobial resistance

Diagnosing Paediatric TB: Challenges and Needs

Q&A: Access to cabotegravir long-acting (CAB-LA) for HIV pre-exposure prophylaxis (PrEP)

Access to TB Testing and Treatments: GeneXpert and Delamanid

Addressing Antimicrobial Resistance Within Global Processes to Improve Pandemic Preparedness and Response

Pandemic Accord: MSF’s Comments on Equity Provisions in INB Proposal for Negotiating Text

Tuberculosis: Challenges and Breakthroughs

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products